389 related articles for article (PubMed ID: 35046095)
1. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Hofmann MH; Gerlach D; Misale S; Petronczki M; Kraut N
Cancer Discov; 2022 Apr; 12(4):924-937. PubMed ID: 35046095
[TBL] [Abstract][Full Text] [Related]
2. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
3.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
4. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
[TBL] [Abstract][Full Text] [Related]
5. KRAS: A Druggable Target in Colon Cancer Patients.
Negri F; Bottarelli L; de'Angelis GL; Gnetti L
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456940
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Targeting KRAS: A Challenging Drug Target.
Wadood A; Ajmal A; Rehman AU
Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
[TBL] [Abstract][Full Text] [Related]
7. Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer.
Li Y; Hu L; Xu C
Curr Opin Oncol; 2022 Jan; 34(1):66-76. PubMed ID: 34690284
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
[TBL] [Abstract][Full Text] [Related]
9. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
[No Abstract] [Full Text] [Related]
10. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
11. Targeting Mutated KRAS Genes to Treat Solid Tumours.
Krishnan T; Roberts-Thomson R; Broadbridge V; Price T
Mol Diagn Ther; 2022 Jan; 26(1):39-49. PubMed ID: 34914038
[TBL] [Abstract][Full Text] [Related]
12. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C; Burkhart DL; Haigis KM
Cancer Discov; 2022 Apr; 12(4):913-923. PubMed ID: 35373279
[TBL] [Abstract][Full Text] [Related]
13. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
14. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo JV; Padda SK
Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
[TBL] [Abstract][Full Text] [Related]
15. Stopping the beating heart of cancer: KRAS reviewed.
Herdeis L; Gerlach D; McConnell DB; Kessler D
Curr Opin Struct Biol; 2021 Dec; 71():136-147. PubMed ID: 34303932
[TBL] [Abstract][Full Text] [Related]
16. The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.
Akhave NS; Biter AB; Hong DS
Mol Cancer Ther; 2022 Nov; 21(11):1645-1651. PubMed ID: 36282862
[TBL] [Abstract][Full Text] [Related]
17. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
18. Reflections on drug resistance to KRAS
Han Z; Zhou D; Wang J; Jiang B; Liu X
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188677. PubMed ID: 35033622
[TBL] [Abstract][Full Text] [Related]
19. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Hofmann MH; Gmachl M; Ramharter J; Savarese F; Gerlach D; Marszalek JR; Sanderson MP; Kessler D; Trapani F; Arnhof H; Rumpel K; Botesteanu DA; Ettmayer P; Gerstberger T; Kofink C; Wunberg T; Zoephel A; Fu SC; Teh JL; Böttcher J; Pototschnig N; Schachinger F; Schipany K; Lieb S; Vellano CP; O'Connell JC; Mendes RL; Moll J; Petronczki M; Heffernan TP; Pearson M; McConnell DB; Kraut N
Cancer Discov; 2021 Jan; 11(1):142-157. PubMed ID: 32816843
[No Abstract] [Full Text] [Related]
20. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
Expert Opin Pharmacother; 2022 Oct; 23(14):1569-1575. PubMed ID: 36217844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]